Jun 24, 2021
MediSieve Raises Additional £1.8 Million in Funding
This investment will fund first-in-man trials investigating the safety and efficacy of the company’s pivotal IL-6 product.
LONDON – June 24, 2021 – MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced a £1.8m investment, led by 24Haymarket. This investment will fund first-inman trials investigating the safety and efficacy of the company’s pivotal IL-6 product.
This year was without a doubt one of the most eventful for MediSieve, even with the pandemic forcing them to change the way the team works. Seeing the potential of its technology to help treat the impact of the cytokine storm commonly experienced during a severe COVID-19 infection, the Company doubled down on its research programme aimed at removing the cytokine IL-6 from the blood.
MediSieve received a £1.6 million UKRI COVID-19 grant to support the first in-human trials of this approach later this year. In addition to making significant progress in research, the team has moved out of its shared laboratory and into a new, fully dedicated laboratory to meet its R&D needs. This gives the Company full control over safety and equipment availability, increasing and improving both safety and experimental capacity. MediSieve continue actively working alongside major industry players and building the trust of the key opinion leaders – in the last few months, the Company has secured a partnership with CADFEM and has been promoted to being a Gold Company within the EIT Health Investor Network.
George Frodsham, CEO of MediSieve, said: “We are delighted to announce this funding round led by 24 Haymarket. It shows great confidence in our technology and business plan, and will enable us to kick-on in this particularly exciting phase for MediSieve.“
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: